TLDR Biotech aims to be your one-stop source for biotech and pharma updates - all with one daily email.

I’m always looking to make these news compilations more informative, impactful, and easy to navigate.

So if you have any feedback on what you like (or don’t), I’d love to hear from you! 📣

And if you like these newsletters and think a friend or colleague would benefit, please share this with them! ♻️

(You can also reach out to me on LinkedIn)

MINOR HOUSEKEEPING
How these updates are formatted

The newsletter is split into three main sections:

• THE GOOD - good news (eg. fundraises, product approvals)

• THE BAD - negative news (eg. clinical trial failures, layoffs)

• THE UGLY - negative but atypical news (lawsuits, product recalls, scandals)

Within each of the three above parts, there are additional sections for easier navigation:

• Eg. There will be multiple “The Good” sections covering things like Fundraises, Approvals, Partnerships etc.

• There will be also additional tags within these sections (Eg. fundraises may mention Stage, product approvals may mention drug name and disease area.)

See something you want to get into further? Click the Read More (goes out to either a news article or a press release).

One last thing; I know paywalls can be annoying, so there’s a [Paywall] tag for any news stories behind one.

ENJOYING THESE NEWSLETTERS?
Consider an optional paid subscription.

TLDR Biotech is currently a one-person show that works full-time to put together these compilations and related content.

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.

THE GOOD
Business Development

Day One Biopharmaceuticals in-licenses ADC from Mabcare Therapeutics
Mabcare receives $55M upfront, $1.152B biobucks
Antibody drug-conjugate, solid tumors, cancer - Read more

Ionis Pharmaceuticals expands licensing agreement with Otsuka Pharmaceuticals
Ionis receives $20M upfront + biobucks (details undisclosed)
Antisense oligonucleotide, hereditary angioedema - Read more

Hikma Pharmaceuticals purchases multiple assets, a manufacturing center, and an R&D centre from Xellia Pharmaceuticals
Xellia receives $135M up-front, $50M biobucks
Anti-infective, infectious disease, injectables - Read more

THE GOOD
Clinical Trials

Taysha Gene Therapies showcases improved motor function in small Rett syndrome gene therapy study
AAV gene therapy, Rett syndrome - Read more

GSK wins big in two Ph3 studies in multiple myeloma
Antibody-drug conjugate, multiple myeloma, cancer - Read more

Intra-Cellular is not depressed by their Ph3 win
Small molecule, depression, major depressive disorder - Read more

Mustang Bio rides higher and higher on positive Ph1/2 data in a rare form of blood cancer
Autologous CAR T cell therapy, Waldenstrom macroglobulinemia, cancer - Read more

THE GOOD
Company Launches

Marea Therapeutics launches with a $190M to go after remnant cholesterol
Monoclonal antibody, cardiometabolic disease, cholesterol - Read more

THE GOOD
Fundraises

Iambic Therapeutics $50M raise
Small molecule, solid tumors, cancer - Read more

Ability Biologics $18M Seed raise
Drug discover, AI, antibody - Read more

Ethris $5M raise
RNA, vaccines, respiratory disease, respiratory infections - Read more

UroGen Pharma public offering, $107.5M
Small molecule, hydrogel, bladder cancer - Read more

Santhera Pharmaceuticals up to CHF69M ($78M) Royalty and Debt Financing
Small molecule, neuromuscular, pulmonary diseases - Read more

Supercede Therapeutics raise (undisclosed amount)
Obesity, weight loss - Read more [Paywall]

THE GOOD
Investments

LFB Manufacturing €20M ($21.4 million) site expansion
Manufacturing, CDMO, recombinant protein, monoclonal antibody - Read more

Primrose Bio investment from 1315 Capital (amount undisclosed)
Manufacturing services, nucleic acids, mRNA, protein - Read more

THE GOOD
Lawsuits

Teva Pharmaceuticals in settlement talks over Medicare kickback DOJ lawsuit
Polypeptide, multiple sclerosis - Read more

THE GOOD
Mergers & Acquisitions

Boston Scientific buys Silk Road Medical for $1.26B
Medical device, carotid artery disease, transcarotid artery revascularization - Read more

THE GOOD
Partnerships

Roche co-development partnership with Ascidian Therapeutics
Ascidian receives $42M upfront, $1.8B biobucks
RNA exon editing, neurological diseases - Read more

Sanofi drug discovery and development partnership with Belharra Therapeutics
Belharra receives $40M upfront and near-time milestone, $700M biobucks
Small molecule, immunology - Read more

UMC Utrecht and VectorY Therapeutics collaborate on ALS Biomarker Study
Amyotrophic lateral sclerosis, biomarker - Read more

THE GOOD
Politics & Policy

FTC backs US antitrust rule changes targeting anticompetitive pharma patent practices
Antitrust, drugs patents - Read more

THE GOOD
Research

What do malaria and polycystic ovary syndrome (PCOS) in common? They could be treatable by the same drug; animal models
Small molecule, malaria, polycystic ovary syndrome - Read more

THE BAD
Clinical Trials

AstraZeneca’s breast cancer Ph3 trial is a triple-negative
Small molecule, breast cancer - Read more

THE UGLY
Clinical Trials

Two patient deaths means Zentalis gets slapped with FDA partial clinical hold
Small molecule, ovarian cancer, uterine carcinoma, sepsis - Read more

THE UGLY
Lawsuits

Kansas AG goes after Pfizer for alleged Covid-19 vaccine misrepresentations
Covid-19 vaccine, safety data - Read more

THE UGLY
Patient Access

If you overdose and you’re on Medicare, it’s unlikely you’ll receive adequate opioid treatments
Opioid addiction, recovery - Read more

Utah - famous for Mormonism and now for unapproved stem cell therapies (as long as your doctor provides you with a waiver)
Stem cell therapy, placental stem cells - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣 

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Want to sponsor this newsletter and reach an audience of 350+ biotech and pharma professionals? Reach us here. 👍

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here.